Patrick Wood, an analyst from Morgan Stanley, maintained the Hold rating on Dexcom. The associated price target is $89.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Patrick Wood has given his Hold rating due to a combination of factors impacting Dexcom. The company has faced significant challenges with the reliability of its G7 device, which have negatively affected its financial performance, particularly in terms of margins and new patient additions. Despite efforts to address these issues, it is expected to take time for investor confidence to be fully restored.
While management has committed to maintaining high-quality standards and there are early signs of improvement, investors remain cautious. Key factors for regaining investor trust include a return to record patient starts, tangible margin improvements, and stable attrition rates. Additionally, an upcoming Investor Event in the first half of 2026 could serve as a potential catalyst for changing the narrative around the company.
According to TipRanks, Wood is an analyst with an average return of -0.5% and a 52.90% success rate. Wood covers the Healthcare sector, focusing on stocks such as TransMedics Group, Becton Dickinson, and Zimmer Biomet Holdings.